Key takeaways
- Gilead raised its 2026 product-sales outlook by US$900 million at the midpoint.
- HIV growth helped lift shares 3.06% on Friday, but annual loss guidance worsened.
- Implied volatility fell after earnings; a higher share price does not necessarily mean richer option premiums.
October 30 close
US$170.68
Regular-session move
+3.06%
+US$5.07
Yahoo share volume
11.36 million
1.91× prior 20-session average
Cboe 30-day IV
31.25%
−3.54 percentage points
2026 product-sales outlook
US$31.0–31.3B
HIV growth lifts the outlook, not every earnings measure
Gilead closed Friday, October 30 at US$170.68, up US$5.07, or 3.06%, from Thursday’s US$165.61 close. Its October 29 release for the quarter ended September 30 showed stronger HIV drug sales and a higher full-year sales outlook. The rally came with an important catch: the company also forecast a deeper annual loss. [1,2]
Third-quarter product sales rose 13% to US$8.289 billion. Total revenue, which also includes royalties and other revenue, increased about 6.8% to US$8.300 billion from US$7.769 billion. Lower royalty and other revenue partly offset product gains. [1]
Yahoo’s completed-session record showed 11,363,966 shares traded, compared with an average 5,950,045 over the preceding 20 sessions: about 1.91 times normal by that specific measure. Cboe confirmed the close. These are Friday’s regular-session figures, retrieved around 19:16 ET, not live after-hours prices. [2,3]
| Measure | Latest result or outlook | Comparison |
|---|---|---|
| Q3 product sales | US$8.289B | US$7.345B a year earlier |
| Q3 GAAP EPS | US$1.94 | US$2.43 a year earlier |
| Q3 non-GAAP EPS | US$2.55 | US$2.47 a year earlier |
| 2026 product-sales guidance | US$31.0–31.3B | Previously US$30.1–30.4B |
| 2026 GAAP loss per share | US$4.40–4.05 loss | Previously US$3.75–3.40 loss |
| 2026 non-GAAP loss per share | US$1.20–0.85 loss | Previously US$0.65–0.30 loss |
What drove the stronger sales
HIV product sales increased 18% to a rounded US$6.2 billion. Gilead cited higher realized prices, stronger prevention demand and favorable inventory movements. Biktarvy sales rose 10% to US$4.1 billion, while Descovy increased 49% to US$1.0 billion. Inventory movements need not reflect lasting patient demand. [1]
- Trodelvy cancer-drug sales rose 42% to US$506 million, adding a growth engine beyond HIV. [1]
- Veklury sales fell 69% to US$86 million as COVID-related hospitalizations declined. [1]
- Cell-therapy sales fell 18% to US$355 million amid competitive pressure: this was not uniform growth across the portfolio. [1]
Management lifted product-sales guidance to US$31.0–31.3 billion from US$30.1–30.4 billion. That raises the midpoint from US$30.25 billion to US$31.15 billion, a US$900 million increase. Excluding Veklury, the new range is US$30.7–31.0 billion, rather than US$29.8–30.1 billion. These are company forecasts, not promised results. [1]
HIV prevention sales nearly doubled year-over-year.
A sales upgrade can sit beside a larger loss
Full-year GAAP loss guidance deepened to US$4.40–4.05 per share, and non-GAAP loss guidance to US$1.20–0.85. Both include roughly US$9.88 per share from acquired research charges of US$12.4 billion, net of the Lakefront collaboration and related taxes. Non-GAAP does not remove every acquisition cost. [1]
A supportive peer backdrop, with limits
Gilead was not the only large drugmaker advancing: Amgen gained 1.15% and Bristol Myers Squibb rose 1.78% on Friday’s closing comparisons. Gilead’s larger gain is consistent with a favorable response to its own report, but these prices cannot prove which headline caused each trade. [2,4,5]
On October 28, the Federal Reserve held its target range at 3.75–4.00%. Two dissenters preferred a quarter-point increase. [6]
GILD: the last 20 completed trading sessions
Unadjusted daily closes, October 5–30, 2026. The final point is the regular-session close, not an after-hours quote.
Source: Yahoo Finance daily-price series [3], retrieved October 30, 2026 around 19:16 ET; final close cross-checked with Cboe [2].
What it means for option sellers
Cboe’s snapshot put 30-day implied volatility at 31.252%, down 3.543 percentage points from the prior reading. Rounded, that is 31.25% versus 34.80%. This is a vendor’s 30-day measure, not the IV of every strike. A reliable current IV rank was not available in the checked evidence, so no rank is assigned. [2]
Lower IV generally reduces an option’s value when other inputs are held constant; a share-price move can work in another direction. Earnings have passed, but that does not make a cash-secured put safe. The wheel can turn a short put into shares after assignment, then a covered call can cap recovery while leaving the stock’s downside largely intact. [9–11]
Payoff arithmetic, not a quoted trade
Assume a hypothetical standard 100-share US$160 put earns US$2 per share: US$200 gross credit against US$16,000 reserved cash. Breakeven is US$158; loss could reach US$15,800 if the stock became worthless, before fees. A hypothetical US$180 covered call caps the share sale price at US$180. No premium, expiry or available contract is being quoted for that call. [9,10]
- These strikes are educational illustrations, not support levels or recommendations; the assumed put premium is not a market quote.
- A real contract would require fresh bid/ask prices, expiry, liquidity and dated-catalyst checks; Friday’s stock close cannot establish the next available option premium.
- Pricing, clinical and acquisition risks can undermine the thesis; an educational monitoring plan would reassess them before relying on assignment or covered calls. [1,9,10]
What to watch next
| Date | Event | Why it matters |
|---|---|---|
| November 6, 08:30 | October U.S. employment report | Potential market-wide rates repricing |
| November 10, 08:30 | October U.S. CPI | Inflation risk before company presentation |
| November 10, 11:20 | Wolfe Research Healthcare Conference | Management’s next listed investor presentation |
| November 17 | UBS and Jefferies conferences | Further management commentary |
| December 15 / December 30 | Dividend record date / payment date | US$0.82 per share; record date is not a verified ex-date |
The next quarterly earnings date was not confirmed on the checked investor-events page; that is an information gap, not proof of an earnings-free holding period. Beyond the near-term calendar, Gilead says Biktarvy’s negotiated Medicare price takes effect January 1, 2028. Pricing, clinical results and acquisition execution remain risks even after a strong sales quarter. [1,14]
Educational news only, not personal financial advice. Selling options can create substantial losses; premium income does not insure the shares. All financial amounts above are in U.S. dollars.
Photo: Coolcaesar / Wikimedia Commons, CC BY 4.0. Archival July 4, 2023 Gilead building photograph; cropped and resized. [12,13]
Sources
- [1]Gilead Q3 2026 results, full-year guidance and dividend — Gilead Sciences · Accessed 2026-10-30T19:16:10.058942-04:00 · Tier 1
- [2]GILD completed-session close and 30-day implied volatility, October 30 — Cboe Global Markets · Accessed 2026-10-30T19:16:10.061669-04:00 · Tier 1
- [3]GILD daily closes and volume through October 30, 2026 — Yahoo Finance · Accessed 2026-10-30T19:16:10.063425-04:00 · Tier 2
- [4]AMGN completed-session close, October 30, 2026 — Cboe Global Markets · Accessed 2026-10-30T19:16:10.062220-04:00 · Tier 1
- [5]BMY completed-session close, October 30, 2026 — Cboe Global Markets · Accessed 2026-10-30T19:16:10.062799-04:00 · Tier 1
- [6]October 28, 2026 FOMC policy statement — Federal Reserve · Accessed 2026-10-30T19:16:10.064281-04:00 · Tier 1
- [7]October 30 announcement of fourth-quarter investor conferences — Gilead Sciences · Accessed 2026-10-30T19:16:10.060448-04:00 · Tier 1
- [8]November 2026 release calendar: employment and CPI — U.S. Bureau of Labor Statistics · Accessed 2026-10-30T19:20:13.414997-04:00 · Tier 1
- [9]Cash-secured put: assignment, breakeven and maximum risk — OCC Options Industry Council · Accessed 2026-10-30T19:16:10.532392-04:00 · Tier 1
- [10]Covered call: capped upside and stock downside — OCC Options Industry Council · Accessed 2026-10-30T19:16:10.671391-04:00 · Tier 1
- [11]Vega: option sensitivity to implied volatility — OCC Options Industry Council · Accessed 2026-10-30T19:16:10.697387-04:00 · Tier 1
- [12]333 Lakeside Drive: archival July 4, 2023 photograph by Coolcaesar — Wikimedia Commons · Accessed 2026-10-30T19:15:02.641406-04:00 · Tier 1
- [13]Creative Commons Attribution 4.0 International license — Creative Commons · Accessed 2026-10-30T19:15:02.641406-04:00 · Tier 1
- [14]Investor events calendar checked for next quarterly earnings date — Gilead Sciences · Accessed 2026-10-30T19:16:10.061102-04:00 · Tier 1
This content is for informational and educational purposes only and is not financial advice. Options involve risk and are not suitable for every investor. Do your own research before trading.
Keep YieldCove close
Choose YieldCove as a preferred source for Top Stories in Google Search.
Run the numbers before you trade: the free wheel strategy calculator sizes the whole cycle, and the cash-secured put calculator shows the cash, return and breakeven of one put.
